INSIGHTS ON CELL & GENE MANUFACTURING AND LOGISTICS

• Advance Your Cell And Gene Therapy With Benchtop Automation

  Automate better biology and accelerate product development with a benchtop platform designed to scale cell therapy manufacturing from R&D to GMP with flexible bioreactors and sterile fluid transfer.

• Trends Shaping The Future Of Cell And Gene Therapy Manufacturing

  Discover how automation and digitalization are transforming cell and gene therapy with scalable, decentralized manufacturing and smarter market navigation.

• Nunc Cell Factory Systems

  Transitioning to biobased materials in cell culture reduces reliance on virgin fossil fuel feedstocks and helps meet Scope 3 emission reduction goals, offering a sustainable path for biomanufacturing.

• Streamlining Tech Transfer And Advancing Next Generation CAR T Therapies

  In this final segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman emphasizes that early engagement between R&D, process development, and manufacturing teams is critical for smooth tech transfer to CDMOs, including using scale-down models, documenting processes thoroughly, and collaborating closely with CDMO staff.

• Balancing Innovation And Flexibility In Early Cell Therapy Manufacturing Technologies

  In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman explains that introducing advanced analytics, automation, and digital tools early can strengthen process control and sterility, but startups must weigh innovation against practical constraints.

• Why Academic Centers Reach The Clinic Faster

  In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman explains that academic institutions often move faster in Phase 1 because many trials are investigator-initiated, allowing streamlined oversight and quicker regulatory engagement, though similar pathways for sponsor-led programs don’t yet exist in the U.S. or EU.

• Building Strong Data Foundations And Smart Logistics For Scalable CGT Development

  In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene emphasize that early investment in analytics and structured data collection is essential to guide scale-up and regulatory success. 

• Are You Still Evaluating CMOs When You Really Need A CDMO?

  Outsourcing adds capacity and specialized knowledge to your supply chain. But contractors come in several types. Here's how to pick the right one.

• Partner Case Study: Accelerating Gene Editing Manufacturing

  Beam Therapeutics partnered with ElevateBio to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.

• Solving The Sequencing Puzzle: Speed, Cost, And Quality

  Next-generation sequencing (NGS) accelerates therapy development by enabling rapid, cost-effective DNA/RNA analysis crucial for cell and gene therapies, process optimization, and impurity detection.